MLTX
MoonLake Immunotherapeutics
NASDAQ · Healthcare · Biotechnology · CH
$15.01
−1.18%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -41.3%
- EBIT
- -33.6%
- EPS
- -38.5%
- Free cash flow
- -35.0%
- Operating cash flow
- -35.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +6.6%
- EPS
- +13.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -83.9%
- EBIT
- -71.1%
- Net income
- -91.1%
- EPS
- -86.8%
- Free cash flow
- -67.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026